Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Mereo BioPharma)"
Count: 51
Selected: 0
| NCT ID | Title |
|---|
| NCT04761198 | A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors. | ||
| NCT03636347 | A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. | ||
| NCT03498170 | The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants | ||
| NCT02926326 | The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers | ||
| NCT02908074 | A 6 Month Safety Extension Study of MBGS205 | ||
| NCT02730169 | Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism | ||
| NCT02700919 | Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease | ||
| NCT01336959 | Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery | ||
| NCT01332097 | Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation | ||
| NCT01200862 | Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men | ||
| NCT01190475 | BGS649 Monotherapy in Moderate to Severe Endometriosis Patients | ||
| NCT01116440 | A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis | ||
| NCT05715216 | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | ||
| NCT05312697 | Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta | ||
| NCT05125809 | Study to Assess Dose, Efficacy and Safety of Setrusumab in Participants With Osteogenesis Imperfecta | ||
| NCT04539795 | COVID-19 Study of Safety and Tolerability of Alvelestat | ||
| NCT03216486 | An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta | ||
| NCT03118570 | A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 | ||
| NCT03986086 | MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | ||
| NCT01806610 | Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease | ||
| NCT01406977 | Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) | ||
| NCT01406548 | Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density | ||
| NCT03679598 | Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency | ||
| NCT03295942 | A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors | ||
| NCT03119428 | A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | ||
| NCT03035253 | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | ||
| NCT03031691 | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | ||
| NCT03030287 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | ||
| NCT02722954 | A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | ||
| NCT02482441 | A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | ||
| NCT02298387 | A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors | ||
| NCT02289898 | Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | ||
| NCT02259582 | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | ||
| NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | ||
| NCT02069145 | Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | ||
| NCT02050178 | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | ||
| NCT02005315 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | ||
| NCT01973309 | A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | ||
| NCT01957007 | A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | ||
| NCT01952249 | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | ||
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy | ||
| NCT01778439 | A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | ||
| NCT01703572 | A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | ||
| NCT01647828 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | ||
| NCT01608867 | A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors | ||
| NCT01345201 | A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors | ||
| NCT01277146 | A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors | ||
| NCT01189968 | A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | ||
| NCT01189942 | A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer | ||
| NCT01189929 | A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer |
